Evolving Paradigms in Oncology

The Evolving Paradigms in Oncology video series features two oncology experts discussing the current landscape state and how it is expected to evolve.

The Role of CD19 in the Targeted Treatment of Relapsed/Refractory DLBCL

The Role of CD19 in the Targeted Treatment of Relapsed/Refractory DLBCL

September 15th 2021

Read More

oncologists

Selective Immunomodulating Microtubule Binding Agents (SIMBA): A Novel Approach To Chemotherapy-Induced Neutropenia

September 2nd 2021

Read More

EGFR Exon 20 Insertion as a Therapeutic Target in Non-small Cell Lung Cancer

EGFR Exon 20 Insertion as a Therapeutic Target in Non-small Cell Lung Cancer

August 12th 2021

Read More

hematologist/oncologist

CD19 As a Therapeutic Target In Diffuse Large B-Cell Lymphoma

July 30th 2021

Read More

hematologists

Targeting JAK2 in Myeloproliferative Neoplasms

July 14th 2021

Read More

The Role of PI3K Inhibitors in Relapsed/Refractory FL and MZL

The Role of PI3K Inhibitors in Relapsed/Refractory FL and MZL

May 20th 2021

Read More

Advances in Later-Lines of Therapy for GIST

Advances in Later-Lines of Therapy for GIST

April 23rd 2021

Read More

Targeting PSMA in Advanced Prostate Cancer

Targeting PSMA in Advanced Prostate Cancer

March 30th 2021

Read More

Examining TKI Combinations in Advanced RCC

Examining TKI Combinations in Advanced RCC

March 30th 2021

Read More

HER2+ BC: A Year in Review and Updates from SABCS

HER2+ BC: A Year in Review and Updates from SABCS

January 19th 2021

Read More

Moving Forward in the Management of Acute GvHD

Moving Forward in the Management of Acute GvHD

December 23rd 2020

Read More

Evolving Approaches for HCC in the Molecular Medicine Era

Evolving Approaches for HCC in the Molecular Medicine Era

November 5th 2020

Read More

Site Logo

Targeted Therapy in Early-Stage HER2+ Breast Cancer

July 31st 2020

Read More

Site Logo

Advancing Survival in Relapsed/Refractory Multiple Myeloma

July 28th 2020

Read More

Site Logo

Expanding Options for Relapsed/Refractory HER2+ Metastatic Breast Cancer

July 7th 2020

Read More

Site Logo

Expanding Options for Relapsed/Refractory Gastrointestinal Stromal Tumors

July 1st 2020

Read More

Site Logo

Targeting KRAS Mutations in Advanced NSCLC

May 27th 2020

Read More

Site Logo

Expanding Options for Treatment of CLL Using BTK Inhibitors

May 8th 2020

Read More

Site Logo

Targeting CD19 in Diffuse Large B-Cell Lymphoma

May 7th 2020

Read More

The Evolving Role of BTK Inhibitors in Treating Chronic Lymphocytic Leukemia

The Evolving Role of BTK Inhibitors in Treating Chronic Lymphocytic Leukemia

April 16th 2020

Read More

Emerging BCMA-directed CAR T-Cell Therapies in RRMM

Emerging BCMA-directed CAR T-Cell Therapies in RRMM

December 24th 2019

Read More

Evolving Role of JAK Inhibitors in Myelofibrosis and Beyond

Evolving Role of JAK Inhibitors in Myelofibrosis and Beyond

December 24th 2019

Read More

BCMA-Targeted Therapy for Relapsed/Refractory Multiple Myeloma

BCMA-Targeted Therapy for Relapsed/Refractory Multiple Myeloma

December 10th 2019

Read More

PARP Inhibition in Ovarian Cancer: BRCA-Mutated and Beyond

PARP Inhibition in Ovarian Cancer: BRCA-Mutated and Beyond

November 18th 2019

Read More

Advances in the Treatment Paradigm for ALK+ NSCLC

Advances in the Treatment Paradigm for ALK+ NSCLC

July 26th 2019

Read More

TRK Inhibitors: A Tumor Agnostic Approach to Treatment of Solid Tumors

TRK Inhibitors: A Tumor Agnostic Approach to Treatment of Solid Tumors

July 15th 2019

Read More

Targeting PD-1 in Non-Melanoma Skin Cancers

Targeting PD-1 in Non-Melanoma Skin Cancers

July 8th 2019

Read More

Frontline CD30 ADC for Advanced Classical Hodgkin Lymphoma

Frontline CD30 ADC for Advanced Classical Hodgkin Lymphoma

June 26th 2019

Read More

BCL2 Inhibition in Leukemia

BCL2 Inhibition in Leukemia

June 25th 2019

Read More

BCR-ABL1 TKIs in Relapsed/Refractory CML

BCR-ABL1 TKIs in Relapsed/Refractory CML

June 24th 2019

Read More

<123>